Patients and caregivers can check whether a medicine they rely on still has an unfinished study that the Food and Drug Administration required after approval. The agency's postmarket requirements and commitments database is free to search by product name. Its current data run through July 31, 2026, and the FDA says it updates the listings quarterly, in January, April, July, and October.
The search is simple, but the results are easy to misread. A "delayed" label is not a finding that a drug is unsafe, and a "pending" label can describe a study that has not enrolled a single patient. For a parent whose child takes a rare-disease drug, knowing the difference can shape the questions asked at the next appointment.
